SCHEDULE 13G/A 0001814554-25-000174 0001281446 XXXXXXXX LIVE 2 Ordinary shares, nominal value 0.01 Euro per share 12/31/2025 0001756594 Inventiva S.A. F5R343107 50 rue de Dijon Daix I0 21121 Rule 13d-1(c) Great Point Partners, LLC DE 0.00 6783269.00 0.00 6783269.00 6783269.00 N 3.49 IA OO Dr. Jeffrey R. Jay, M.D. X1 0.00 6783269.00 0.00 6783269.00 6783269.00 N 3.49 HC IN Ms. Lillian Nordahl X1 0.00 6783269.00 0.00 6783269.00 6783269.00 N 3.49 HC IN Inventiva S.A. 50 rue de Dijon, 21121 Daix France Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated February 17, 2026, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830 Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States. Y 6,783,269 3.49% 0 6,783,269 0 6,783,269 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 194,410,831 shares outstanding, which is the sum of (i) 191,077,498 share outstanding as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission (the "SEC") on November 28, 2025 and (ii) 3,333,332 shares of Common Stock issuable upon exercise of Warrants held by the reporting persons (subject to the Beneficial Ownership Cap). In addition to an aggregate of 3,449,937 shares of the Issuer's common stock (the "Common Stock") in the aggregate held outright, the reporting persons hold in the aggregate warrants to purchase 3,333,332 shares of Common Stock. All shares underlying such warrants are beneficially owned by the reporting persons. N Y N See Item 4. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D 02/17/2026 Dr. Jeffrey R. Jay, M.D. /s/ Dr. Jeffrey R. Jay, M.D 02/17/2026 Ms. Lillian Nordahl /s/ Ms. Lillian Nordahl 02/17/2026